Vantage logo

The future of renal denervation

The pivotal trial of Medtronic’s hypertension device came out more than a year ago, yet the company has still not sought approval.

Vantage logo

Kizoo aims to cure ageing

The German tech investor Kizoo Ventures is committing €300m of its own cash to biotech start-ups working on rejuvenation and healthy lifespan expansion.

Vantage logo

Esker joins the Tyk2 race

The new group reckons it has the most selective Tyk2 inhibitor yet. Patenting it is another issue.